SINOVAC BIOTECH LTD

Drug Name	Phase	Indication	Designations	Patent
control live attenuated mumps vaccine	Phase 3	Mumps	-	-
36-71 months old children-experimental EV71 vaccine.	Phase 3	Hand, Foot and Mouth Disease	-	-
investigational 23-valent PPV	Phase 3	Pneumococcal Infections	-	-
400U /0.5ml EV71 vaccine	Phase 3	Hand, Foot and Mouth Disease	-	-
Investigational sIPV	Phase 3	Poliomyelitis	-	-
three consecutive lots of EV71 vaccine	Phase 3	Hand, Foot and Mouth Disease	-	-
Three doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of age	Phase 3	Poliomyelitis	-	-
Quadrivalent influenza vaccine	Phase 3	Seasonal Influenza	-	-
Quadrivalent influenza vaccine(0.25ml)	Phase 3	Seasonal Influenza	-	-
bivalent enterovirus vaccine (Vero cell), inactivated	Phase 3	Hand, Foot, and Mouth Disease（HFMD)	-	-
Sabin Strain Inactivated Poliovirus Vaccine	Phase 3	Poliomyelitis	-	-
Participants will receive one dose of vaccine (0.5 mL) of Sinovac QIV	Phase 3	Influenza	-	-
Investigational tetanus vaccine, adsorbed	Phase 3	Tetanus	-	-
Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14	Phase 3	Covid19	-	-
Vaccine manufactured at commercialized scale	Phase 3	Varicella	-	-
Sinovac PCV13	Phase 3	Pneumococcal Infectious Disease	-	-
investigational live attenuated mumps vaccine	Phase 3	Mumps	-	-
PROVARIX	Phase 3	Varicella (Chickenpox)	-	-
Inactivated COVID-19 Vaccine	Phase 3	COVID-19	-	-
Investigational live attenuated varicella vaccine	Phase 3	Varicella	-	-
COVID-19 Vaccine,Inactivated	Phase 3	COVID-19	-	-
Varicella Vaccine	Phase 3	Varicella	-	-
COVID-19 Vaccine (Vero cell), Inactivated (Omicron variant)	Phase 3	COVID-19	-	-
Sinovac rabies vaccine	Phase 3	Rabies (Healthy Volunteers)	-	-
sIPV-sIPV-bOPV vaccination schedule	Phase 3	Poliomyelitis	-	-
Trivalent influenza vaccine (contains B/Victoria strain)	Phase 3	Seasonal Influenza	-	-
sIPV-bOPV-bOPV vaccination schedule	Phase 3	Poliomyelitis	-	-
Quadrivalent influenza vaccine(0.5ml)	Phase 3	Seasonal Influenza	-	-
Influenza Vaccine (Split Virion), Inactivated, Quadrivalent	Phase 3	Seasonal Influenza	-	-
Experimental vaccine	Phase 3	Poliomyelitis	-	-
Single-dose regimen of high dosage investigational sIPV	Phase 2	Poliomyelitis	-	-
SARS-CoV-2 Inactivated Vaccine	Phase 2	COVID-19	-	-
Sinovac PCV24	Phase 2	Pneumococcal Infectious Disease	-	-
pandemic influenza vaccine (H5N1 strain NIBRG-14)	Phase 2	Pandemic Influenza	-	-
100U EV71 vaccine with adjuvant	Phase 2	Infection, Viral, Enterovirus	-	-
COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain	Phase 2	COVID-19	-	-
split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)	Phase 2	Influenza	-	-
Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule	Phase 2	COVID-19	-	-
SNA02-48	Phase 2	Tetanus	-	-
Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28	Phase 2	COVID-19	-	-
Sinovac Low-dosage PCV24	Phase 2	Pneumococcal Infectious Disease	-	-
Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28	Phase 2	COVID-19	-	-
Oral hexavalent reassortant rotavirus attenuated live vaccine	Phase 2	Rotavirus Gastroenteritis	-	-
Low-dose experimental vaccine	Phase 2	Herpes Zoster	-	-
low dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated	Phase 2	Hand, Foot and Mouth Disease	-	-
Low-dose of tetravalent inactivated enterovirus vaccine (Vero cell)	Phase 2	Hand, Foot, and Mouth Disease (HFMD)	-	-

📑

Catalyst DossierPRO

The full research note — thesis, the if-approved scenario, financials & smart money. Compiled by CeliA.

→

Catalyst Verdict

Full breakdown — the signals behind the verdict

Market-Implied Move

Regulatory Approvals

Frequently asked questions

What is in SINOVAC BIOTECH LTD's drug pipeline?→

CatalystAlert tracks 46 drug candidates in SINOVAC BIOTECH LTD's (SVA) pipeline across Phase 3, Phase 2. Its lead program is control live attenuated mumps vaccine (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is SINOVAC BIOTECH LTD's next FDA catalyst?→

SINOVAC BIOTECH LTD's (SVA) next tracked catalyst is a Phase 2 expected June 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track SVA biotech catalysts?→

Add SVA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow SINOVAC BIOTECH LTD's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

SINOVAC BIOTECH LTD

Market Overview

SVA News

Catalyst Timeline

PROVARIX Phase 3 Est. Readout

Pipeline & FDA Submissions

AI Predictions & Institutional Flow

Market Intelligence

Regulatory Approvals

Frequently asked questions